Alaunos Therapeutics, Inc. (TCRT)
Nasdaq · Healthcare · Biotechnology
$0.7953−3.01%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.3M
- 52-week range
- $0.7761 – $4.59
- 52-week change
- −72.67%
- EPS (trailing)
- −$1.76
Fiscal year to Dec 2025
- Revenue
- $5K (−50.00%)
- Net income
- −$4.2M
- Operating margin
- −84500.0%
- Diluted EPS
- −$2.20
- Free cash flow
- −$3.0M
From the company’s annual report on SEC EDGAR.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Headquarters: Fort Lauderdale, United States · 1 employees · alaunos.com